Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional)
ID: 357284Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357284

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-25-034.html
Timeline
    Description

    The National Institutes of Health (NIH) is inviting applications for the "Novel Assays to Address Translational Gaps in Treatment Development" initiative, aimed at advancing neurophysiological measures that can serve as assays for drug and device therapies in mental health research. This funding opportunity encourages collaborative partnerships among neuroscientists to optimize in vivo testing in both preclinical species and humans, with a focus on bridging the gap between preclinical and clinical measures to enhance therapeutic outcomes for mental disorders. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, and foreign entities, with key deadlines including an application due date of January 21, 2025, and a funding expiration on June 21, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-25-034.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and the National Institute of Mental Health (NIMH), invites applications for the "Novel Assays to Address Translational Gaps in Treatment Development" (Funding Opportunity Number PAR-25-034). This initiative aims to advance the development of neurophysiological measures that could serve as assays for drug and device therapies in mental health research. The funding encourages collaborative partnerships among neuroscientists focused on optimizing in vivo testing in both preclinical species and humans. Projects will undergo a two-phase evaluation process: the UG3 phase for feasibility studies and the UH3 phase for testing these assays with pharmacologic manipulations. Key dates include an application due date on January 21, 2025, and a funding expiration on June 21, 2025. Eligible applicants encompass a broad spectrum of organizations, including higher education institutions, nonprofits, and foreign entities. Essential submission guidelines emphasize adherence to detailed instructions for application preparation. Ultimately, this funding opportunity seeks to bridge the gap between preclinical and clinical measures to improve therapeutic outcomes for mental disorders, marking a significant shift in the evaluation of novel treatments.
    Similar Opportunities
    Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for Research Project Grants (R01) aimed at the development of screening assays for drug candidates targeting psychiatric disorders. The primary objectives of this initiative are to stimulate research in the discovery and development of novel small molecules that can potentially treat mental illnesses, as well as to validate compounds that demonstrate desired biological activity through rigorous screening processes. This funding is crucial for advancing therapeutic options for conditions such as depression, schizophrenia, and PTSD, and it encourages applicants to align their proposals with the National Institute of Mental Health (NIMH) priorities. Interested applicants must submit their proposals by May 7, 2026, and can find additional information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering Innovation Grants to Nurture Initial Translational Efforts (IGNITE) aimed at developing assays and identifying therapeutic agents for neurological and neuromuscular disorders. This funding opportunity encourages research grant applications focused on assay development and iterative screening to characterize potential therapeutics, operating under the R61/R33 phased award mechanism that requires progression based on achieving specific milestones. The initiative is crucial for advancing scientific knowledge and addressing significant health challenges, with a total estimated program funding of $750,000 and an award ceiling of $750,000. Applications are due starting January 18, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Neuromodulation/Neurostimulation Device Development for Mental Health Applications," aimed at advancing the development of innovative brain stimulation devices for mental health disorders. This initiative seeks applications that either create novel brain stimulation technologies or significantly enhance existing FDA-approved devices through improvements in hardware and software, focusing on increased spatiotemporal precision and multi-focal, closed-loop approaches. The program is particularly important for addressing limitations in current mental health treatments and fostering technological innovation in this field. Interested applicants can apply for grants up to $275,000 for a two-year project period, with applications due by January 7, 2028. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-286.html.
    Translational Neural Devices (R61/R33 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Neural Devices (R61/R33 - Clinical Trial Optional)" aimed at advancing the development of therapeutic and diagnostic devices for neurological and neuromuscular disorders. This initiative encourages investigators to engage in translational activities and small clinical studies, focusing on the implementation of clinical prototype devices, non-clinical safety and efficacy testing, and obtaining necessary regulatory approvals for clinical trials. The program emphasizes a milestone-driven approach, requiring collaboration with NIH staff throughout the project, and aims to address health disparities in neurological health. Interested applicants, including various educational and community organizations, must submit their proposals by January 28, 2027, and can find additional information and application guidelines at NIH Grants.
    National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the National Cooperative Drug/Device Discovery/Development Groups (NCDDG) funding opportunity, aimed at advancing innovative therapies for mental disorders through cooperative agreements. This initiative encourages applications focused on the discovery, preclinical development, and proof of concept testing of new pharmacological agents and neuromodulatory devices, with a strong emphasis on partnerships between academia and industry. The program is designed to facilitate the transition of drug and device solutions from discovery to early human trials, addressing critical mental health challenges. Interested applicants must comply with NIH registration and submission requirements, with application deadlines beginning on January 25, 2025, and funding awards potentially lasting up to five years. For further details, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-352.html.
    Translational Neural Devices (R61/R33 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "Translational Neural Devices (R61/R33 - Clinical Trial Optional)" aimed at advancing the development of therapeutic and diagnostic devices for neurological and neuromuscular disorders. This funding opportunity supports projects through two phases: R61 for non-clinical activities and R33 for small clinical studies, with a focus on ensuring compliance with Environmental Health and Safety regulations. The program emphasizes diversity in applicant teams and requires a Plan for Enhancing Diverse Perspectives, with key deadlines including submission openings starting December 28, 2024, and a close date of January 28, 2027. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R01 Clinical Trial Not Allowed)" aimed at advancing the development of innovative brain stimulation devices for mental health treatment. This initiative seeks applications that either create novel devices or significantly enhance existing FDA-approved devices through hardware and software improvements, focusing on increased precision and effectiveness in treatment. The funding underscores the importance of multidisciplinary collaboration in neuroscience and engineering, with an emphasis on innovative approaches rather than incremental changes. Interested applicants can find more information and submit proposals by January 7, 2028, with no budget cap but a maximum project duration of five years. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-287.html.
    National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional)," aimed at advancing the discovery and development of innovative treatments for mental disorders, including substance use disorders and alcohol use disorder. This initiative encourages collaborative efforts between academia and industry to support multidisciplinary research projects that focus on early-stage human studies and the development of novel therapeutic candidates and neuromodulation tools. The program is designed to complement private sector efforts and emphasizes the importance of data sharing and innovative approaches to mental health treatment challenges. Interested applicants must adhere to specific eligibility criteria and application instructions, with a submission opening date of January 25, 2025, and a total project period not exceeding five years. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-353.html.
    Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R01 Clinical Trial Optional)." This initiative aims to support invasive neural recording studies that investigate the neural circuitry and dynamics associated with mental health disorders, encouraging researchers to address specific questions with high translational potential. The program emphasizes the importance of innovative collaborations in neuroscience and engineering to enhance understanding and therapeutic approaches for mental health challenges. Applications will open on January 5, 2025, with a project duration of up to five years and no budget limits. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-290.html.
    Discovery of in vivo Chemical Probes for the Nervous System
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at supporting the discovery of in vivo chemical probes for the nervous system, specifically targeting novel brain mechanisms. This initiative, led by the National Institute on Aging (NIA) in collaboration with the National Eye Institute (NEI), the National Institute on Drug Abuse (NIDA), and the National Institute of Mental Health (NIMH), seeks applicants who possess validated starting compounds for chemical optimization and bioassays to explore new analog compounds. The focus will be on developing small molecules that can enhance understanding of biological processes relevant to brain diseases, with an emphasis on innovative biological targets. Interested applicants can reach out to Dr. Paul G. Grothaus at grothausp@mail.nih.gov or call 240-688-6634 for further information, with the estimated synopsis posting date set for February 26, 2026, and a projected award date of April 5, 2027.